Real-Life Peak and Trough Dabigatran Plasma Measurements Over Time in Hospitalized Geriatric Patients with Atrial Fibrillation

被引:15
|
作者
Chaussade, E. [1 ,2 ]
Hanon, O. [1 ,2 ]
Boully, C. [1 ,2 ]
Labouree, F. [1 ,2 ]
Caillard, L. [1 ,2 ]
Gerotziafas, G. [3 ,4 ]
Vidal, J. -S. [1 ,2 ]
Elalamy, I. [3 ,4 ]
机构
[1] Hop Broca, AP HP, Paris, France
[2] Univ Paris 05, Sorbonne Paris Cite, Equipe Accueil 4468, Paris, France
[3] Hop Tenon, HUEP, AP HP, Serv Hematol Biol, Paris, France
[4] UPMC Paris 6, UMR S 938, Paris, France
关键词
Anticoagulants; antithrombins; atrial fibrillation; aged; 80 and over; ORAL ANTICOAGULANTS; ELDERLY-PATIENTS; ANTITHROMBOTIC THERAPY; COAGULATION ASSAYS; DRUG-THERAPY; RISK; WARFARIN; STROKE; PHARMACOKINETICS; METAANALYSIS;
D O I
10.1007/s12603-017-0982-4
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Few geriatric patients were included in studies on direct oral anticoagulants and data on dabigatran concentration and safety are needed in this population. Our objectives were to evaluate peak and trough dabigatran plasma concentrations over time in a geriatric population and to identify factors associated with dabigatran plasma concentrations and to assess the relationship with bleeding events. Peak and trough dabigatran plasma concentration were performed 4,8,15,30,45 days after inception of dabigatran treatment in 68 consecutive patientsae<yen>75 years old hospitalized in a geriatric hospital with atrial fibrillation. Bleeding events were monitored for 1 year. Mean age was 85.8(5.1) years old and 76.5% were women. Overall, 541 dabigatran plasma measurements (270 peak, 271 trough) were performed. Mean dabigatran concentrations of the 5 sequential measurements ranged 106-146ng/mL for peak and 66-84ng/mL for trough. Renal failure was associated with high peak and trough dabigatran concentration. Inter- and intra-individual coefficients of variation were 59.5% and 44.7% for peak and 74.5% and 44.6% for trough. Participants in the lower two tertiles of dabigatran concentration at day 8 (D8) remained below the 90(th) percentile (243.9ng/ml) on the next measurements. Bleeding events were associated with high trough dabigatran concentrations. Trough dabigatran concentration at D8 > 243.9ng/mL significantly predicted bleeding. In this geriatric population, renal function and low albumin were associated with dabigatran concentrations. Despite large variability, participants in the lower two tertiles of dabigatran concentration at D8 remained below the 90(th) percentile on the following measurements. D8 dabigatran trough concentrationae<yen>243.9ng/mL identified patients at risk of bleeding.
引用
收藏
页码:165 / 173
页数:9
相关论文
共 50 条
  • [21] Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis
    Escobar, Carlos
    Marti-Almor, Julio
    Perez Cabeza, Alejandro
    Jose Martinez-Zapata, M.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2019, 72 (04): : 305 - 316
  • [22] EFFECTIVENESS OF CONTROL OVER HEMODYNAMIC INDEXES AND PROGNOSIS FOR PATIENTS WITH CHF AND ATRIAL FIBRILLATION IN REAL-LIFE CLINICAL PRACTICE
    Vinogradova, N. G.
    Fomin, I., V
    Polyakov, D. S.
    Zhirkova, M. M.
    Tyurin, A. A.
    Krylova, A. N.
    Samarina, A. S.
    Allakhverdieva, S. M.
    KARDIOLOGIYA, 2018, 58 : 43 - 53
  • [23] Real-life Dabigatran Patient Selection: Change Over Time and Compared to the RE-LY Study Population
    Leach, Molly C.
    Spencer, Anne P.
    CIRCULATION, 2012, 126 (21)
  • [24] Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study
    Russo, Vincenzo
    Attena, Emilio
    Mazzone, Carmine
    Melillo, Enrico
    Rago, Anna
    Galasso, Gennaro
    Riegler, Lucia
    Parisi, Valentina
    Rotunno, Raffaele
    Nigro, Gerardo
    D'Onofrio, Antonio
    CLINICAL THERAPEUTICS, 2019, 41 (08) : 1598 - 1604
  • [25] Real-life anticoagulation treatment of atrial fibrillation after catheter ablation: Possible overtreatment of low-risk patients
    Dagres, Nikolaos
    Hindricks, Gerhard
    Kottkamp, Hans
    Sommer, Philipp
    Gaspar, Thomas
    Bode, Kerstin
    Arya, Arash
    Rallidis, Loukianos S.
    Kremastinos, Dimitrios Th
    Piorkowski, Christopher
    THROMBOSIS AND HAEMOSTASIS, 2009, 102 (04) : 754 - 758
  • [26] Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation
    Abrignani, Maurizio Giuseppe
    Lombardo, Alberto
    Braschi, Annabella
    Renda, Nicolo
    Abrignani, Vincenzo
    Lombardo, Renzo M.
    WORLD JOURNAL OF CARDIOLOGY, 2022, 14 (11): : 576 - 598
  • [27] Stroke and Bleeding Risks in Patients with Atrial Fibrillation Treated with Reduced Apixaban Dose: A Real-Life Study
    Salameh, Maram
    Gronich, Naomi
    Stein, Nili
    Kotler, Antonio
    Rennert, Gad
    Auriel, Eitan
    Saliba, Walid
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (06) : 1265 - 1273
  • [28] Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years
    Romagnoli, Alessia
    Santoleri, Fiorenzo
    Costantini, Alberto
    Di Risio, Angelora
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2024, 31 (02) : 156 - 161
  • [29] Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale
    Turk, Ugur Onsel
    Alioglu, Emin
    Mavioglu, Zafer
    Diker, Erdem
    Ozpelit, Ebru
    De Caterina, Raffaele
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2022, 50 (02): : 117 - +
  • [30] The Trends in Utilizing Nonvitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: A Real-Life Experience
    Avci, Burcak Kilickiran
    Vatan, Bulent
    Tok, Ozge Ozden
    Aidarova, Tamara
    Sahinkus, Salih
    Uygun, Turgut
    Gunduz, Huseyin
    Karakaya, Osman
    Yuksel, Husniye
    Ongen, Zeki
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2016, 22 (08) : 785 - 791